im96 car-t cells
Colorectal (Colon or Rectal) Cancer
Beijing Immunochina Medical Science & Technology Co., Ltd.Cell therapyPhase 1Active
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 35/ 100
- Competitive Position
- 95/ 100
Competitive context
839 Active assets in the Colorectal (Colon or Rectal) Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Desflurane Peter MacCallum Cancer Centre, Australia | Phase 4 | BBB |
MARBLE DUST James Varani | Phase 2/3 | BB |
FLUOROURACILUM Washington University School of Medicine | Phase 4 | BB |
PANITUMUMAB M.D. Anderson Cancer Center | Phase 3 | BB |
Cetuximab Shanghai Henlius Biotech | Phase 4 | BB |
View all 50 →
Same molecule, other indications
im96 car-t cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →